Compare GE & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GE | AZN |
|---|---|---|
| Founded | 1892 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.8B | 276.3B |
| IPO Year | N/A | 1993 |
| Metric | GE | AZN |
|---|---|---|
| Price | $307.99 | $91.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $311.00 | N/A |
| AVG Volume (30 Days) | 5.1M | ★ 5.8M |
| Earning Date | 01-22-2026 | 02-05-2026 |
| Dividend Yield | 0.48% | ★ 1.69% |
| EPS Growth | 31.94 | ★ 45.02 |
| EPS | ★ 7.50 | 6.02 |
| Revenue | $43,950,000,000.00 | ★ $58,127,000,000.00 |
| Revenue This Year | $10.94 | $11.33 |
| Revenue Next Year | $11.72 | $6.08 |
| P/E Ratio | $40.22 | ★ $15.05 |
| Revenue Growth | ★ 17.68 | 13.52 |
| 52 Week Low | $159.36 | $61.24 |
| 52 Week High | $316.67 | $94.02 |
| Indicator | GE | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 59.89 | 56.59 |
| Support Level | $291.62 | $89.85 |
| Resistance Level | $308.06 | $91.79 |
| Average True Range (ATR) | 7.09 | 1.30 |
| MACD | 2.14 | -0.27 |
| Stochastic Oscillator | 98.48 | 79.54 |
GE Aerospace is the global leader in designing, manufacturing, and servicing commercial aircraft engines, along with partner Safran in their CFM joint venture. With its massive global installed base of nearly 70,000 commercial and military engines, GE Aerospace earns most of its profits on recurring service revenue of that equipment, which operates for decades. GE Aerospace is the remaining core business of the company formed in 1892 with historical ties to American inventor Thomas Edison; that company became a storied conglomerate with peak revenue of $130 billion in 2000 until GE spun off its appliance, finance, healthcare, and wind and power businesses between 2016 and 2024.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.